This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
JAK3-IN-11
Catalog No. T9811 CAS
2412734-00-8
JAK3-IN-11 (Compound 12) exhibits potent, noncytotoxic, irreversible, orally active JAK3 inhibitory activity (IC50 = 1.7 nM) with an excellent selectivity profile (<588-fold compared to other JAK isoforms), covalently binds to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T-cell proliferation which is a promising tool for studying autoimmune diseases [1].
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
Contact us for more batch information
Biological Description
Chemical Properties
Storage
& Solubility Information
Description
JAK3-IN-11 (Compound 12) exhibits potent, noncytotoxic, irreversible, orally active JAK3 inhibitory activity (IC50 = 1.7 nM) with an excellent selectivity profile (>588-fold compared to other JAK isoforms), covalently binds to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T-cell proliferation which is a promising tool for studying autoimmune diseases [1].
In vitro
JAK3-IN-11 (Compound 12) demonstrates no significant cytotoxic effects at a concentration of 10 μM over 72 hours. It exhibits potent suppression of T cell proliferation, with IC 50 values of 0.83 μM and 0.77 μM under anti-CD3/CD28 and IL-2 stimulation respectively, indicating strong immunosuppressive activity through selective inhibition of JAK3. Additionally, JAK3-IN-11 inhibits IL-2 or IL-15-induced phosphorylation of STAT5 in a dose-dependent manner within 1 hour, ranging from 0-10 μM. This compound notably binds covalently and irreversibly to JAK3, highlighting its targeted action on this kinase. The observed effects were supported by cell proliferation assays using mouse T cells and Western blot analysis for phosphorylation status, underscoring the compound's effectiveness in modulating relevant immune pathways.
In vivo
JAK3-IN-11 (Compound 12) effectively inhibits oxazolone (OXZ)-induced delayed-type hypersensitivity (DTH) in Balb/c mice in a dose-dependent manner, administered orally at doses of 0-30 mg/kg before and throughout a 6-day challenge phase. This compound was tested in an animal model specifically designed to induce DTH responses with OXZ. The study observed varying doses of 30, 10, and 3 mg/kg showing a dose-dependent reduction in DTH responses. Additionally, in male ICR mice, preliminary pharmacokinetic analysis of JAK3-IN-11 was conducted, demonstrating significant data following oral gavage and intravenous administration at doses of 30 mg/kg and 10 mg/kg, respectively. Key pharmacokinetic parameters were measured, including area under the concentration-time curve (AUC(0-t) and AUC(0-∞)), mean residence time (MRT), steady-state volume (Vz), plasma clearance (CLz), terminal half-life (t 1/2), peak plasma concentrations (C max), and bioavailability, revealing insights into the compound's absorption, distribution, metabolism, and excretion properties.
Molecular Weight
401.46
Formula
C23H23N5O2
CAS No.
2412734-00-8
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dose Conversion
You can also refer to dose conversion for different animals.
More
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.